Belfast, Northern Ireland, 05/20/2025
Sonrai Analytics (Sonrai), a leader in AI precision medicine, and AOA Dx (AOA), an early-stage biotech company developing the first test to diagnose ovarian cancer in symptomatic women, today announced a strategic partnership to accelerate the development of AOA’s multi-omic liquid biopsy test. The partnership aims to advance the development of the diagnostic test through a multi-omic biomarker validation strategy.
Through the partnership, AOA will leverage Sonrai’s cloud-based advanced analytics platform, pharma-grade data infrastructure and bioinformatic expertise to integrate and analyze multi-modal data, including multi-omic and clinical data. The platform will support AOA in validating diagnostic biomarkers, enhancing the accuracy and clinical utility of its serum-based test for ovarian cancer. The test leverages a combination of novel gangliosides, lipids, and proteins to diagnose ovarian cancer in women experiencing vague abdominal symptoms. Diagnosing women when symptoms first occur could transform the pathway for women, and ultimately change outcomes, whilst offering significant savings to healthcare systems.
In addition, Sonrai will offer its bioinformatics expertise, enabling AOA to harness pre-built machine learning tools and run automated pipelines, all within a secure, cloud-native environment. The Sonrai Discovery platform will enable AOA to store and manage their clinical data in role-based environments that allow controlled access, workspace isolation, cross-functional collaboration, and real-time performance tracking, to ensure security, governance, and compliance.
“We’re delighted to partner with AOA Dx to help advance the development of their innovative test for ovarian cancer. By applying our AI-powered analytics platform, we’re able to unlock deeper insights from complex multi-modal data, accelerating the validation of biomarkers, enabling earlier and more accurate detection.” said Prof. Darragh McArt, CEO and Founder, Sonrai Analytics.
“By partnering with Sonrai, we can not only integrate and manage our in-house development data but also cross-reference it with public datasets and analyze it seamlessly within one centralized environment.” said Dr Abigail McElhinny, Chief Scientific Officer, AOA Dx. “The ability to combine and analyze multi-omic, clinical, and demographic data within one compliant platform is critical to both our research and regulatory approval process.”
Together, Sonrai and AOA are driving innovation where it’s needed most, improving outcomes for patients facing one of the most challenging cancers to diagnose early. This partnership reflects both companies’ commitment to innovation in precision medicine, turning complex data into life-saving diagnostics for women around the world.
About Sonrai Analytics
Sonrai Analytics, founded in 2018, is an AI precision medicine technology company. Sonrai’s flagship product, Sonrai Discovery, expedites identifying and developing drug or therapeutic targets, improving patient outcomes through AI. The company partners with biotechnology and pharmaceutical companies to manage and analyze their precision medicine data. By leveraging Sonrai Discovery, these companies can confidently select compounds with the highest potential for success in clinical trials, accelerating drug development and mitigating the risk of failures during human trials.
With a proven track record, Sonrai has successfully deployed its technology with prominent healthcare businesses across the EU and the US. Additionally, Sonrai continues to forge strategic partnerships (including NHS) that will further enhance commercial operations and scale impact.
For additional information about Sonrai, please visit: sonraianalytics.com. To speak with one of our experts, book a chat with us here.
About AOA Dx
AOA Dx is transforming cancer detection with its proprietary GlycoLocate™ platform, a first-of-its-kind, multi-omics liquid biopsy that integrates gangliosides, lipids, proteins, and clinical data using advanced machine learning. The company’s lead test, AKRIVIS GD™, is designed to diagnose ovarian cancer in symptomatic women, where no other diagnostic currently exists and more than 70% of women are diagnosed at stages III or IV when the 5-year survival rate is less than 30%. Based in Denver, Colorado, AOA is led by an experienced team of scientists and industry experts and has developed an R&D laboratory focused on identifying and validating novel biomarkers pioneering the future of cancer diagnostics.